trending Market Intelligence /marketintelligence/en/news-insights/trending/fEEFiE1gOm4pbsNHKQqCkA2 content esgSubNav
In This List

M Pharmaceutical unit changing name to Callitas Therapeutics

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


M Pharmaceutical unit changing name to Callitas Therapeutics

M Pharmaceutical Inc. announced that it is changing the name and branding of its unit M Pharmaceutical USA to Callitas Therapeutics Inc. The name of the parent company will remain as it is for now, the company said in a release.

Callitas was formed in 2015 as a clinical-stage company developing technologies for obesity, weight management, and female health and wellness. In addition to its recent acquisitions of C-103, a reformulation of Orlistat and assets from 40J’s LLC, M Pharma is scheduled to launch their FDA-cleared fertility product branded as ToConceive sometime in September.